[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-bis[(2-aminoacetyl)oxy]-10,13-dimethyl-17-[(1R)-1-methyl-4-oxo-4-[[1-[6-[4-[[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-tris[(2-aminoacetyl)oxy]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]methyl]triazol-1-yl]hexyl]triazol-4-yl]methylamino]butyl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]2-aminoacetate hexahydrochloride

ID: ALA5185395

Chembl Id: CHEMBL5185395

PubChem CID: 168280649

Max Phase: Preclinical

Molecular Formula: C72H122Cl6N14O14

Molecular Weight: 1401.80

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@H](CCC(=O)NCc1cn(CCCCCCn2cc(CNC(=O)CC[C@@H](C)[C@H]3CC[C@H]4[C@@H]5[C@H](OC(=O)CN)C[C@@H]6C[C@H](OC(=O)CN)CC[C@]6(C)[C@H]5C[C@H](OC(=O)CN)[C@]34C)nn2)nn1)[C@H]1CC[C@H]2[C@@H]3[C@H](OC(=O)CN)C[C@@H]4C[C@H](OC(=O)CN)CC[C@]4(C)[C@H]3C[C@H](OC(=O)CN)[C@]12C.Cl.Cl.Cl.Cl.Cl.Cl

Standard InChI:  InChI=1S/C72H116N14O14.6ClH/c1-41(49-13-15-51-67-53(29-57(71(49,51)5)99-65(93)35-77)69(3)21-19-47(95-61(89)31-73)25-43(69)27-55(67)97-63(91)33-75)11-17-59(87)79-37-45-39-85(83-81-45)23-9-7-8-10-24-86-40-46(82-84-86)38-80-60(88)18-12-42(2)50-14-16-52-68-54(30-58(72(50,52)6)100-66(94)36-78)70(4)22-20-48(96-62(90)32-74)26-44(70)28-56(68)98-64(92)34-76;;;;;;/h39-44,47-58,67-68H,7-38,73-78H2,1-6H3,(H,79,87)(H,80,88);6*1H/t41-,42-,43+,44+,47-,48-,49-,50-,51+,52+,53+,54+,55-,56-,57+,58+,67+,68+,69+,70+,71-,72-;;;;;;/m1....../s1

Standard InChI Key:  GRAWTMCLOZZSEK-JPSCQWQKSA-N

Associated Targets(non-human)

Staphylococcus aureus (210822 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Enterococcus faecium (13803 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
3LL cell line (138 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 1401.80Molecular Weight (Monoisotopic): 1400.8795AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Saini V, Mehta D, Gupta S, Kumar S, Rani P, Rana K, Rajput K, Jain D, Pal G, Aggarwal B, Pal S, Gupta SK, Kumar Y, Ramu VS, Bajaj A..  (2022)  Targeting Vancomycin-Resistant Enterococci (VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide Conjugates.,  65  (22.0): [PMID:36331380] [10.1021/acs.jmedchem.2c01293]

Source